Harrow, Inc. (NASDAQ:HROW) Shares Sold by New York State Common Retirement Fund

New York State Common Retirement Fund lowered its stake in shares of Harrow, Inc. (NASDAQ:HROW) by 36.9% in the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 13,901 shares of the company’s stock after selling 8,126 shares during the period. New York State Common Retirement Fund’s holdings in Harrow were worth $466,000 at the end of the most recent reporting period.

Other institutional investors have also recently added to or reduced their stakes in the company. Mirae Asset Global Investments Co. Ltd. boosted its position in shares of Harrow by 21.5% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,283 shares of the company’s stock worth $57,000 after buying an additional 227 shares during the period. Quest Partners LLC acquired a new position in Harrow during the 3rd quarter worth about $29,000. China Universal Asset Management Co. Ltd. boosted its holdings in Harrow by 10.7% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 7,552 shares of the company’s stock valued at $253,000 after acquiring an additional 727 shares during the period. Calamos Advisors LLC grew its position in Harrow by 35.2% in the 4th quarter. Calamos Advisors LLC now owns 11,913 shares of the company’s stock valued at $400,000 after acquiring an additional 3,103 shares in the last quarter. Finally, Bleakley Financial Group LLC increased its stake in Harrow by 63.1% during the fourth quarter. Bleakley Financial Group LLC now owns 8,770 shares of the company’s stock worth $294,000 after purchasing an additional 3,394 shares during the period. Institutional investors and hedge funds own 72.76% of the company’s stock.

Harrow Stock Performance

Shares of Harrow stock opened at $26.11 on Wednesday. The business has a 50-day simple moving average of $32.20 and a 200-day simple moving average of $39.84. The company has a debt-to-equity ratio of 3.23, a quick ratio of 1.44 and a current ratio of 1.55. Harrow, Inc. has a one year low of $9.30 and a one year high of $59.23. The company has a market cap of $929.91 million, a PE ratio of -27.78 and a beta of 0.69.

Analysts Set New Price Targets

Several research analysts have recently commented on the stock. HC Wainwright started coverage on shares of Harrow in a research note on Thursday, February 6th. They issued a “buy” rating and a $57.00 price objective for the company. B. Riley decreased their price target on shares of Harrow from $73.00 to $69.00 and set a “buy” rating for the company in a research report on Wednesday, December 4th.

About Harrow

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.